Nicole Lamanna

Statistics

Publications

Citations

7.9K

H-Index

Active since

2003

Affiliations

Columbia University Irving Medical Center(Current)

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Dana-Farber Cancer Institute

University of Pennsylvania

Nicole Lamanna is an author at Columbia University Irving Medical Center specializing in medicine, chronic lymphocytic leukemia therapy, and immunotherapy.

ORCID

Publications per year

2003–2025

Publications

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen et al. · New England Journal of Medicine · 2022 · 457 citations · Full text

Medicine, Oncology, Pharmacology +16

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 454 citations · Full text

Medicine, Oncology, Pharmacology +12

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson et al. · Haematologica · 2018 · 452 citations · Full text

Medicine, Oncology, Pharmacology +12

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jeffrey A. Jones, Anthony R. Mato, William G. Wierda et al. · The Lancet Oncology · 2017 · 378 citations · Full text

Life Sciences, Hematology, Immunology +12

1–5 of 87